Go Deep
Strides Pharma Science Limited
Strides Pharma Science Limited Score & Ratio Trend
| Date | Score | P/E | P/B | D/E | Price |
|---|---|---|---|---|---|
| Oct 2026 | 20,801 | 16.2 | 3.20 | 0.56 | 1,080.00 |
| Oct 2026 | 20,290 | 16.5 | 3.25 | 0.56 | 1,096.20 |
Strides Pharma Science Limited Quarterly Results
| Line Item | Jun 2026 | Mar 2026 | Dec 2025 | Jun 2025 |
|---|---|---|---|---|
| Revenue | 12,654,070,000.0 | 13,234,700,000.0 | 11,946,460,000.0 | 11,197,360,000.0 |
| Net Profit | 1,569,140,000.0 | 1,269,440,000.0 | 2,021,070,000.0 | 996,080,000.0 |
| EPS | 17.0 | 13.8 | 21.9 | 10.8 |
Strides Pharma Science Limited Revenue & Profit: Last 5 Years
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Revenue | 46,279,660,000.0 | 43,916,820,000.0 | 37,300,230,000.0 | 36,076,690,000.0 | — |
| Net Profit | 5,561,930,000.0 | 35,934,550,000.0 | -706,120,000.0 | -2,026,350,000.0 | — |
| EPS | 60.3 | 390.6 | -7.8 | -22.5 | — |
Strides Pharma Science Limited Balance Sheet
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Total Assets | 69,272,320,000.0 | 60,487,250,000.0 | 58,397,550,000.0 | 66,384,200,000.0 | — |
| Total Liabilities | 37,778,950,000.0 | 34,622,610,000.0 | 37,680,470,000.0 | 44,655,370,000.0 | — |
| Total Equity | 31,075,650,000.0 | 25,518,310,000.0 | 21,255,650,000.0 | 22,122,580,000.0 | — |
Owes vs Owns
Strides Pharma Science Limited owed ₹0.55 for every ₹1 it owned in Mar 2026, down from ₹0.67 in Mar 2023.
| Period | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Owes vs Owns | 0.55× | 0.57× | 0.65× | 0.67× |
Everything the company owes ÷ everything it owns. Below 1× it owns more than it owes; above 1× it owes more than it owns.
Strides Pharma Science Limited Assets & Liabilities Breakdown (₹ Cr)
What it owns — Mar 2026
Cash & short-term investments 3.0%Receivables 18.6%Inventory 23.6%Fixed assets (tangible) 17.1%Intangible assets 20.1%Other assets 17.5%
How it's funded — Mar 2026
Short-term debt 16.1%Long-term debt 8.0%Payables 18.9%Other liabilities 11.5%Shareholders' equity 45.5%
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Assets | ||||
| Cash & short-term investments | 204.5 | 198.6 | 289.6 | 360.7 |
| Receivables | 1,289.0 | 1,202.9 | 1,141.9 | 1,299.4 |
| Inventory | 1,634.8 | 1,277.6 | 1,126.2 | 1,146.5 |
| Fixed assets (tangible) | 1,183.0 | 1,018.4 | 977.3 | 1,392.0 |
| Intangible assets | 1,394.1 | 1,114.5 | 1,056.5 | 1,076.9 |
| Long-term investments | 12.5 | 10.7 | 189.3 | 385.9 |
| Other assets | 1,209.4 | 1,225.9 | 1,059.0 | 977.0 |
| Liabilities & equity | ||||
| Short-term debt | 1,116.4 | 1,224.4 | 1,743.0 | 1,634.7 |
| Long-term debt | 552.3 | 571.2 | 671.5 | 1,139.8 |
| Payables | 1,309.7 | 1,032.5 | 851.6 | 982.3 |
| Other liabilities | 799.5 | 634.1 | 501.9 | 708.7 |
| Shareholders' equity | 3,149.3 | 2,586.5 | 2,071.7 | 2,172.9 |
| Net tangible assets | 1,713.5 | 1,437.3 | 1,069.0 | 1,135.4 |
Strides Pharma Science Limited Cash Flow
| Line Item | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|
| Operating Activities | 7,025,190,000.0 | 6,843,740,000.0 | 7,010,650,000.0 | 444,110,000.0 | — |
| Investing Activities | -1,730,360,000.0 | -896,890,000.0 | -1,502,500,000.0 | 3,024,740,000.0 | — |
| Financing Activities | -4,534,090,000.0 | -6,425,810,000.0 | -6,933,230,000.0 | -2,139,210,000.0 | — |